Neuraxpharm Group has acquired two product portfolios for central nervous system disorders from Sanofi.

With this deal, Neuraxpharm strengthens its position as a specialty pharmaceutical company focused on CNS.

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, said, “There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven by an aging population and an increasing awareness of mental health. This phenomenon is a global trend. With the upcoming acquisition, we will not only strengthen our presence in Europe but also lay the ground for further expanding our international presence.”